TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Power of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuity of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response to treatment (corrected serum calcium concentration normalized)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission to hospital or ED visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall satisfaction with rigid lens wear
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adaptation perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tissue water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of heaviness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: Osteocalcin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean measured intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to obtain bilateral satisfactory Pascal readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty of tonometry score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean reductions in HAM-D(17) total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D(17) response or remission after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of EUS in estimating invasive depth of gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of EUS in estimating lymphatic metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum MMP-9 levels correlation with invasive degree and staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from treatment failure (FFTF)
Endpoint domain: Mortality/survival
Primary endpoint: Arterial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Access to continuous EEG monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Availability of protocol for CRSE management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of potentially harmful supplement use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEWL values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: individual's global assessment score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRSA bacteremia rates
Endpoint domain: Adverse events/effects
Primary endpoint: CAUTI rates
Endpoint domain: Adverse events/effects
Primary endpoint: CLABSI rates
Endpoint domain: Adverse events/effects
Primary endpoint: CDI rates
Endpoint domain: Adverse events/effects
Primary endpoint: POCD incidence
Endpoint domain: Mortality/survival
Primary endpoint: Visual analog pain scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IL-1β, IL-6, and TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neonatal birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailable 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LL-37 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice therapy superiority
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time off work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of nonunion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vasomotor instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to discuss withdrawal of life support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MACE (Major Adverse Cardiac Events)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients free from angina
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of developing major depression
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in performance on the metronome-assisted task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in LV systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak early diastolic velocity (Em)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/e'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volumes of cerebral gray and white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volumes of orbitofrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volumes of hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volumes of white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of patients with visceral hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in signs and symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spleen size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-wave amplitude increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wattpeak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in home medication-related discrepancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF/flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weight-for-age Z
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: arm muscle area-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower limbs strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue domain of the HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sleep Latency (SL)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wake After Sleep Onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total Sleep Time (TST)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Daily OFF- and ON-times improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of febrile responses
Endpoint domain: Adverse events/effects
Primary endpoint: Screening for diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No disease flare
Endpoint domain: Adverse events/effects
Primary endpoint: Serum IgG, IgA, C3 and C4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of chronic wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of maternal motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of instrumental vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrauterine adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adhesion scores using AFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HIV‐1 RNA levels less than 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Waiting time to first appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of postbronchoscopy fever
Endpoint domain: Adverse events/effects
Primary endpoint: Development of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IL-6 concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rectal mucosal release of SP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac dysfunction complications
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of recalled information sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation rates at the sixth cycle
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Six-cycle discontinuation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Side effects of COCs
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival (PFS) rate after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Overall Survival (OS) time
Endpoint domain: Mortality/survival
Primary endpoint: Maximum ankle torque values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase I ankle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBP, DBP, and HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment discontinuation rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean time to all-cause discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Satiation rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin response (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bronchopulmonary dysplasia (BPD) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: degree of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sodium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: platelet recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gamma-survival
Endpoint domain: Mortality/survival
Primary endpoint: itching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjunctival redness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chemosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in gross motor and fine motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity for identification of polyps 0.5 cm or larger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for identification of large polyps (> or =1‐cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ATS-negative urine tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of days abstinent from ATS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: curative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Left Ventricular (LV) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inpatient hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healthcare expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disability from headache
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lost workdays due to headache
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean intensity of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global assessment of hand pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height increment (DeltaHT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth velocity (GV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Satisfaction score with ClozeX
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cosmetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoporosis assessment questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-evaluation of competence and behaviour-change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to reversal of vecuronium-induced block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of reparalysis
Endpoint domain: Adverse events/effects
Primary endpoint: number of reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean proximal extent of reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bolus clearance times of reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rates
Endpoint domain: Adverse events/effects
Primary endpoint: MPA(t) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FeNO level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ≥1-grade composite response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological impact of SMF and satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: healthy food purchasing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ALSFRS-R decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: 6-Minute Walk Distance (6-MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to task failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVC force decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central drive reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ACL injury rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lequesne index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bronchial secretion viscosity and adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LP/PMM EI ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound visibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected visual acuity (VA) of 0.2 LogMAR or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: need for post-operative blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: microleakage at the enamel margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of mandibular movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score
Endpoint domain: Adverse events/effects
Primary endpoint: discomfort score
Endpoint domain: Adverse events/effects
Primary endpoint: Use of intervention items
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rhodes index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total amount of anti-emetic tablets
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean incision perfusion in fluorescent units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean perfusion impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Histological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological cores obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum amplitude (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time (r)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord serum ferritin (SF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mismatch Negativity (MMN) response to nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urea clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evidence for tachyphylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative rupture rate of the cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportions of HLA-DR positive T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of T-killer/effector cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in hyperandrogenism symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection time from event onset to physician evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes